FDC2024-04-012024-06-30 FDC2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member FDC2024-06-30 FDC2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 531599 FDC NOTLISTED FDC Limited Equity 2024-04-01 2025-03-31 2024-08-07 2024-07-26 INR Lakhs First quarter 12:00:00 14:45:00 2024-08-07 2024-08-07 Not applicable Single segment Pharmaceutical Business 2024-04-01 2024-06-30 Unaudited Standalone 6241412000.00 281530000.00 6522942000.00 1351419000.00 315061000.00 607924000.00 1159385000.00 12915000.00 109953000.00 1390696000.00 4947353000.00 1575589000.00 0.00 1575589000.00 360000000.00 65700000.00 425700000.00 0.00 1149889000.00 0.00 0.00 0.00 0.00 1149889000.00 2608000.00 1152497000.00 1152497000.00 0.00 162810000.00 1 7.06 7.06 0.00 0.00 7.06 7.06 0.00 0.00 0.00 1. The above unaudited standalone financial results which are published in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) for the quarter ended June 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 7, 2024. The Statutory Auditors have carried out a limited review of the above results and have expressed an unmodified review conclusion. 2. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3. Figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year ended as on March 31, 2024 and the published year-to-date figures up to end of the third quarter ended as on December 31, 2023 of the relevant financial year. Also, the figures upto the end of third quarter had only been reviewed and not subjected to audit. 4. The Company has only one segment of activity namely “Pharmaceuticals”. 5. The above results are also available on the website of the Company i.e. www.fdcindia.com and on the website of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com. Other Expenses 1390696000.00 Amount of items that will not be reclassified to profit and loss 2962000.00 2962000.00 354000.00 0.00